Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study

Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes. It has extrapancreatic hypoglycemic effects, which makes it a good candidate in type 1 diabetes (T1D). In previous studies, we have shown that a gliclazide-bile acid mixture exerted a hypoglycemic effect in a rat model of T1D....

Full description

Bibliographic Details
Main Authors: Mooranian, Armin, Negrulj, Rebecca, Chen-Tan, Nigel, Al-Sallami, H., Fang, Zhongxiang, Mukkur, Trilochan, Mikov, Momir, Golocorbin-Kon, S., Fakhoury, M., Arfuso, Frank, Al-Salami, Hani
Format: Journal Article
Published: Dove Medical Press Ltd. 2014
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/19308
_version_ 1848749996224020480
author Mooranian, Armin
Negrulj, Rebecca
Chen-Tan, Nigel
Al-Sallami, H.
Fang, Zhongxiang
Mukkur, Trilochan
Mikov, Momir
Golocorbin-Kon, S.
Fakhoury, M.
Arfuso, Frank
Al-Salami, Hani
author_facet Mooranian, Armin
Negrulj, Rebecca
Chen-Tan, Nigel
Al-Sallami, H.
Fang, Zhongxiang
Mukkur, Trilochan
Mikov, Momir
Golocorbin-Kon, S.
Fakhoury, M.
Arfuso, Frank
Al-Salami, Hani
author_sort Mooranian, Armin
building Curtin Institutional Repository
collection Online Access
description Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes. It has extrapancreatic hypoglycemic effects, which makes it a good candidate in type 1 diabetes (T1D). In previous studies, we have shown that a gliclazide-bile acid mixture exerted a hypoglycemic effect in a rat model of T1D. We have also shown that a gliclazide-deoxycholic acid (G-DCA) mixture resulted in better G permeation in vivo, but did not produce a hypoglycemic effect. In this study, we aimed to develop a novel microencapsulated formulation of G-DCA with uniform structure, which has the potential to enhance G pharmacokinetic and pharmacodynamic effects in our rat model of T1D. We also aimed to examine the effect that DCA will have when formulated with our new G microcapsules, in terms of morphology, structure, and excipients’ compatibility. Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G-SA (control) at a ratio of 1:30, and G-DCA-SA (test) at a ratio of 1:3:30. Complete characterization of microcapsules was carried out. The new G-DCA-SA formulation was further optimized by the addition of DCA, exhibiting pseudoplastic-thixotropic rheological characteristics. The size of microcapsules remained similar after DCA addition, and these microcapsules showed no chemical interactions between the excipients. This was supported further by the spectral and microscopy studies, suggesting microcapsule stability. The new microencapsulated formulation has good structural properties and may be useful for the oral delivery of G in T1D.
first_indexed 2025-11-14T07:29:48Z
format Journal Article
id curtin-20.500.11937-19308
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T07:29:48Z
publishDate 2014
publisher Dove Medical Press Ltd.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-193082017-09-13T13:47:27Z Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study Mooranian, Armin Negrulj, Rebecca Chen-Tan, Nigel Al-Sallami, H. Fang, Zhongxiang Mukkur, Trilochan Mikov, Momir Golocorbin-Kon, S. Fakhoury, M. Arfuso, Frank Al-Salami, Hani polymer gliclazide type 2 diabetes bile acids Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes. It has extrapancreatic hypoglycemic effects, which makes it a good candidate in type 1 diabetes (T1D). In previous studies, we have shown that a gliclazide-bile acid mixture exerted a hypoglycemic effect in a rat model of T1D. We have also shown that a gliclazide-deoxycholic acid (G-DCA) mixture resulted in better G permeation in vivo, but did not produce a hypoglycemic effect. In this study, we aimed to develop a novel microencapsulated formulation of G-DCA with uniform structure, which has the potential to enhance G pharmacokinetic and pharmacodynamic effects in our rat model of T1D. We also aimed to examine the effect that DCA will have when formulated with our new G microcapsules, in terms of morphology, structure, and excipients’ compatibility. Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G-SA (control) at a ratio of 1:30, and G-DCA-SA (test) at a ratio of 1:3:30. Complete characterization of microcapsules was carried out. The new G-DCA-SA formulation was further optimized by the addition of DCA, exhibiting pseudoplastic-thixotropic rheological characteristics. The size of microcapsules remained similar after DCA addition, and these microcapsules showed no chemical interactions between the excipients. This was supported further by the spectral and microscopy studies, suggesting microcapsule stability. The new microencapsulated formulation has good structural properties and may be useful for the oral delivery of G in T1D. 2014 Journal Article http://hdl.handle.net/20.500.11937/19308 10.2147/DDDT.S65396 Dove Medical Press Ltd. fulltext
spellingShingle polymer
gliclazide
type 2 diabetes
bile acids
Mooranian, Armin
Negrulj, Rebecca
Chen-Tan, Nigel
Al-Sallami, H.
Fang, Zhongxiang
Mukkur, Trilochan
Mikov, Momir
Golocorbin-Kon, S.
Fakhoury, M.
Arfuso, Frank
Al-Salami, Hani
Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
title Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
title_full Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
title_fullStr Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
title_full_unstemmed Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
title_short Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
title_sort novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study
topic polymer
gliclazide
type 2 diabetes
bile acids
url http://hdl.handle.net/20.500.11937/19308